Ocrevus may help treat MS paramagnetic rim lesions

A recent analysis has shown that Ocrevus (ocrelizumab) might have a positive effect on paramagnetic rim lesions (PRLs) in people living with multiple sclerosis (MS). PRLs are a type of long-lasting inflammatory lesion that has been linked to worsening disability in MS.

These lesions are often marked by an iron rim, which indicates the presence of iron-rich immune cells surrounding the area. They also show a loss of myelin – the protective coating around nerve cells that gets damaged in MS.

The new findings revealed that people treated with Ocrevus saw reductions in iron within these lesions, as well as signs of increased myelin, suggesting some repair might be happening.

Together, the results suggest that Ocrevus treatment could help reduce harmful inflammation and support myelin repair in people with PRLs, according to Kimberly Markowitz from Cornell University, New York.

The research was shared during a presentation at the ACTRIMS Forum 2025, which took place from Wednesday 27 February to Saturday 1 March 2025, both in Florida and online.